Published in Hepatology on February 28, 2014
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol (2014) 2.85
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84
Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model. J Invest Dermatol (2015) 1.39
Antiarrhythmic agents and the risk of malignant neoplasm of liver and intrahepatic bile ducts. PLoS One (2015) 1.37
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96
Cancer biomarker discovery and validation. Transl Cancer Res (2015) 0.96
The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene (2015) 0.95
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov (2016) 0.92
Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol (2015) 0.91
EGFR Signaling in Liver Diseases. Int J Mol Sci (2015) 0.90
Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling. Oncotarget (2015) 0.87
β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. J Hepatol (2015) 0.86
Erlotinib might be a double-edged sword in HCC. Hepatology (2014) 0.82
Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clin Gastroenterol Hepatol (2015) 0.81
New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials. Front Pharmacol (2016) 0.81
Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS One (2014) 0.81
Safety and feasibility of laparoscopic hepatectomy for hepatocellular carcinoma in the posterosuperior liver segments. World J Surg (2015) 0.81
Plumbagin Ameliorates CCl 4 -Induced Hepatic Fibrosis in Rats via the Epidermal Growth Factor Receptor Signaling Pathway. Evid Based Complement Alternat Med (2015) 0.81
Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer (2016) 0.80
Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model. Hepatology (2016) 0.79
In vitro reversion of activated primary human hepatic stellate cells. Fibrogenesis Tissue Repair (2015) 0.79
Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget (2016) 0.79
Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma. Sci Bull (Beijing) (2015) 0.78
UNC50 prompts G1/S transition and proliferation in HCC by regulation of epidermal growth factor receptor trafficking. PLoS One (2015) 0.78
Common pathway signature in lung and liver fibrosis. Cell Cycle (2016) 0.77
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. Cancer Chemother Pharmacol (2015) 0.77
Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol (2015) 0.77
Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediators Inflamm (2016) 0.77
Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice. Cancer Sci (2015) 0.77
Lung Infection by Human Bocavirus Induces the Release of Profibrotic Mediator Cytokines In Vivo and In Vitro. PLoS One (2016) 0.77
Oxidative stress and cell damage in a model of precancerous lesions and advanced hepatocellular carcinoma in rats. Toxicol Rep (2014) 0.76
Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesis. Am J Physiol Gastrointest Liver Physiol (2015) 0.76
Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis. J Am Soc Nephrol (2015) 0.76
Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Front Pharmacol (2016) 0.76
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27. J Exp Clin Cancer Res (2016) 0.76
Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies. Curr Pathobiol Rep (2014) 0.76
Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells. Sci Rep (2017) 0.75
CXCL4 Contributes to the Pathogenesis of Chronic Liver Allograft Dysfunction. J Immunol Res (2016) 0.75
Effect of Exogenous Fetuin-A on TGF-β/Smad Signaling in Hepatic Stellate Cells. Biomed Res Int (2016) 0.75
Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. World J Gastroenterol (2016) 0.75
Hepatocyte ERBB3 and EGFR are required for maximal CCl4-induced liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
SYSTEM-WIDE MAPPING OF ACTIVATED CIRCUITRY IN EXPERIMENTAL SYSTEMIC INFLAMMATORY RESPONSE SYNDROME. Shock (2016) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
Reply: To PMID 24677197. Hepatology (2014) 0.75
Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes. Cancer Res (2016) 0.75
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol (2016) 0.75
Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events. BMC Genomics (2015) 0.75
Kenneth tanabe works to solve the mysteries of liver cancer: while progress has been relatively slow, this noted expert sees reasons for hope. P T (2015) 0.75
Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi. Am J Transl Res (2016) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
T2 relaxation time is related to liver fibrosis severity. Quant Imaging Med Surg (2016) 0.75
Tumor regulation of the tissue environment in the liver. Pharmacol Ther (2017) 0.75
The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. Mol Cell Oncol (2017) 0.75
RASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis. Oncotarget (2017) 0.75
Blocking fibrotic signaling in fibroblasts from patients with carpal tunnel syndrome. J Cell Physiol (2017) 0.75
miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut (2017) 0.75
Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. Oncotarget (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hepatocellular carcinoma. Lancet (2003) 22.54
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 16.74
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev (2008) 10.28
TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med (2007) 9.77
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Liver cirrhosis. Lancet (2008) 6.11
Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res (2009) 3.70
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology (2009) 2.16
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology (2013) 2.13
The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci U S A (2007) 2.00
Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology (2003) 1.97
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA (2008) 1.94
Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology (2012) 1.91
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology (2005) 1.90
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer (2007) 1.83
Chronic hepatitis: morphology and nomenclature. Mod Pathol (1994) 1.64
Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res (2007) 1.54
Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol (2010) 1.49
Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol (1998) 1.39
The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) (2009) 1.31
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol (2012) 1.28
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20
Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem (2000) 1.15
Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene (1995) 1.08
Heparin-binding epidermal growth factor-like growth factor suppresses experimental liver fibrosis in mice. Lab Invest (2012) 0.93
Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int J Mol Med (2007) 0.91
Bile acid-induced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis. J Biol Chem (2009) 0.88
Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C. Cytokine (2011) 0.87
Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver. Korean J Hepatol (2007) 0.86
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. Clin Exp Immunol (2012) 0.84
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell (2009) 6.23
Pancreatic adenocarcinoma. N Engl J Med (2014) 6.21
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A (2010) 6.15
The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21